to page content
to site navigation
The Foundation's primary site.
Global news, events, and resources.
The national learning program for entrepreneurs.
A new approach to developing the next generation of high-growth firms.
Access to university research and innovation.
The Kauffman Foundation's charter school serving Kansas City.
Encouraging the aspirations of young people.
The platform for business plan competitions.
College preparation and access for urban youth in Kansas City.
A guide to Kauffman Foundation and partner resources, for aspiring entrepreneurs.
News and announcements from the Foundation.
From our vice president of Entrepreneurship.
From our vice president of Advancing Innovation.
News from Global Entrepreneurship Week
News about this education program for entrepreneurs.
Tweets for the eMed Community at Entrepreneurship.org
News from the Kauffman Labs program.
From our business plan competition service.
Contribute to the community seeking to improve entrepreneurship and innovation measurement.
A look at entrepreneurship from the Kauffman Foundation's Thom Ruhe.
Tracks research and policies that are accelerating economic growth and changing the world.
Brings to light various policies and initiatives to advance innovation and drive economic growth.
A selection of our videos
Take our video and audio with you.
Explore many of our publications.
Join the discussion on our LinkedIn site.
Join us on Google's social service.
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
A new Kauffman Foundation report points to what might be a long-term bridge over the most difficult funding stage for startups—the 'Valley of Death.' In that timeframe, after entrepreneurs have exhausted friends, family, and personal credit and before they're ready for external funding, some startups struggle to raise enough capital to stay alive.
Any entrepreneur who hopes to raise capital from individual investors, so-called "angels," should be properly prepared with a presentation, business plan, list of potential angels, and outline of the opportunity his or her new venture affords. The author explains that it's also important to avoid making such mistakes as allowing investors to have too large a stake in the enterprise. That could cause problems should the company fail, he writes, in an article filled with specific tips for dealing with these financiers.
William Sahlman is the Dimitri V. d'Arbeloff - Class of 1955 Professor of Business Administration at Harvard Business School. The d'Arbeloff Chair was established in 1986 to support teaching and research on the
entrepreneurial process. The Chair honors the late Dimitri d'Arbeloff (HBS '55), whose entrepreneurial skills helped make Millipore Corporation a world leader in its industry. Mr. Sahlman received an A.B. degree in Economics from Princeton
University, an M.B.A. from Harvard University, and a Ph.D. in Business Economics, also from Harvard. His research focuses on the investment and financing decisions made in entrepreneurial ventures at all stages in their development. Mr.
Sahlman was co-chair of the Entrepreneurship and Service Management Unit from 1999 to 2002. From 1991 to 1999, he was Senior Associate Dean, Director of Publishing Activities, and chairman of the board for Harvard Business School
Publishing Corporation. From 1990 to 1991, he was chairman of the Harvard University Advisory Committee on Shareholder Responsibility. He is a member of the board of directors of several private companies.
After coaching others in spin control for years, a cash-strapped entrepreneur had to face the music-and the media-himself. He drew on long-cultivated relationships to tell his story accurately and bring his business out of receivership. Being both proactive and honest, he says, is essential in a crisis situation.
Women and minorities are offered tactics for honing their approach to angel investors, who are largely white and male, from an entrepreneur who consults in the field.
Beth joined Kleiner Perkins Caufield & Byers in May 2005 to work in life sciences. For the past 20 years, she has focused her career on introducing new innovative treatments for AIDS, arthritis, asthma, cancer,
psoriasis, cardiovascular, metabolic, neurological and renal disorders. Seidenberg has introduced 10 innovative products to market and achieved over 40 regulatory approvals, including new indications and formulations, worldwide. These
products have been successfully commercialized and provided benefits to millions of patients with grievous illnesses, and they have generated several billion dollars of revenue. Prior to joining KPCB, Beth was Senior Vice President, Global
Development, and Chief Medical Officer at Amgen, Inc., the world's largest biotechnology company. During Beth's three years there, her responsibilities included all stages of clinical research, regulatory affairs, safety, health
economics/reimbursement and medical affairs. During her tenure, five innovative products were approved for commercial use. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb Company and
Merck & Co., Inc. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases. Beth received her BS from Barnard College magna cum laude, Phi Beta Kappa;
and her medical degree from the University Of Miami School Of Medicine, alpha omega alpha. Her post-graduate training was completed at Johns Hopkins, George Washington School of Medicine and the National Institutes of Health. She is a
member of the Johns Hopkins Bloomberg School of Public Health Advisory Board and Barnard College Science Advisory Board.
New healthcare businesses in some medical cities may benefit from the Occupy Wall Street movement. Read more about how cities in areas without state incentives for investment could be better off in the near future.
How do medical device startups and other new healthcare businesses get investments? They need to know how to answer some key questions, according to the manager of the West Health Investment Fund.
Investments in digital health are on the rise this year, both in terms of the amount of dollars invested and the number of companies getting investment deals. Read more about this trend.
Non-dilutive funding offers startups a lot of advantages, but some entrepreneurs get caught up chasing too many grants. Read more about choosing which funding sources to pursue.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.
© 2013 Ewing Marion Kauffman Foundation. All Rights Reserved.